- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1206EUR$1,250USD£1,035GBP
- Report
- March 2024
- 257 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- February 2024
- 184 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 178 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 181 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- January 2024
- 101 Pages
North America
From €1448EUR$1,500USD£1,242GBP
- Report
- January 2024
- 109 Pages
Middle East, Africa
From €1448EUR$1,500USD£1,242GBP
- Report
- March 2018
- 280 Pages
Global
From €2316EUR$2,400USD£1,987GBP
- Report
- January 2023
- 110 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- August 2020
- 80 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- August 2022
- 117 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- April 2021
China
From €2510EUR$2,600USD£2,153GBP
- Report
- January 2019
- 16 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- January 2019
- 23 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- January 2019
- 51 Pages
Global
From €9652EUR$10,000USD£8,279GBP
Ibrutinib is a type of drug used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a type of targeted therapy, meaning it works by targeting specific proteins in cancer cells. It is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), an enzyme involved in the growth and survival of cancer cells. Ibrutinib works by blocking the activity of BTK, which helps to stop the growth and spread of cancer cells.
Ibrutinib is approved by the US Food and Drug Administration (FDA) for the treatment of CLL and SLL. It is also approved for the treatment of Waldenström's macroglobulinemia, a type of non-Hodgkin's lymphoma. It is available in both oral and intravenous forms.
Ibrutinib is marketed by several companies, including Janssen Pharmaceuticals, AbbVie, and Pharmacyclics. It is also available as a generic drug in some countries. Show Less Read more